Overview

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Status:
Completed

Trial end date:
2017-01-18

Target enrollment:

Participant gender:

Summary

To determine the efficacy of oral APL-1202 administered consecutively for 12 weeks in subjects with high-risk NMIBC relapsed from intravesical chemo/BCG therapy based on the recurrence-free rate (RFR) at 12 months after APL-1202 treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu Yahong Meditech Co., Ltd aka Asieris
Jiangsu Yahong Meditech Co.,Ltd.